|
2026 Journal Article Co-designing primary and secondary outcome measures for an international phase 3 trial of surgical de-escalation in vulvar cancer through a consumer workshopAngel, Lauren, Janda, Monika, Martin, Andrew, Armstrong, Brianna, Williams, Merran, Thaler, Nicola Du, Wild, Emma, Li, Mary and Obermair, Andreas (2026). Co-designing primary and secondary outcome measures for an international phase 3 trial of surgical de-escalation in vulvar cancer through a consumer workshop. Research Involvement and Engagement, 12 (1) 91, 1. doi: 10.1186/s40900-026-00902-8 |
|
2026 Journal Article ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerWilliams, Scott, Sweeney, Christopher J., Thomas, Hayley, Mak, Blossom, Zhang, Alison, Lim, Tee Sin, Jose, Chakiath, Martin, Jarad, Patanjali, Nitya, Pryor, David, Tran, Phuong, Mangar, Stephen, Mihai, Alina M., Thomas, Carys, Gampenrieder, Simon, Yip, Sonia, Cheung, Leanna, Lee, Sandra, Goodwin, Annabelle, Haworth, Annette, Walsh, Anna, Kelly, Paul J., Hughes, Simon, Martin, Andrew, McDermott, Ray, Stockler, Martin, Davis, Ian D. and Nguyen, Paul L. (2026). ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer. Journal of Clinical Oncology 10.1200/JCO-26-01794. doi: 10.1200/jco-26-01794 |
|
2026 Journal Article Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)Law, Chi Kin, Stockler, Martin R., Martin, Andrew J., Davis, Ian D., Sweeney, Christopher J. and Morton, Rachael L. (2026). Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304). Eclinicalmedicine, 100 104207, 104207. doi: 10.1016/j.eclinm.2026.104207 |
|
2026 Journal Article Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Sartor, Oliver, Morris, Michael J., Subramaniam, Shalini, Crumbaker, Megan, Ayati, Narjess, Chen, Jeffrey, Herrmann, Ken, Gafita, Andrei, Swiha, Mina, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Ho, Bao, Khan, Sobia, Tan, Thean Hsiang, Bills, Madison, Nguyen, Andrew, Thein, Thida, Sidhom, George, Wong, Keith, Martin, Andrew James, Hofman, Michael S., Sandhu, Shahneen ... Davis, Ian D. (2026). Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). European Urology. doi: 10.1016/j.eururo.2026.03.026 |
|
2026 Journal Article PREDICTING RESPONSE OF EARLY-STAGE ENDOMETRIOID ADENOCARCINOMA TO LEVONORGESTREL INTRAUTERINE DEVICE: DEVELOPMENT AND EVALUATION OF A PROGNOSTIC RISK MODEL FROM THE FEMME PHASE II RANDOMIZED TRIALBaxter, Eva, Robledo, Kristy, Dissanayake, Sadrushi, Cummings, Margaret, Smith, Deborah, Alizart, Michelle, Walsh, Michael, Kutasovic, Jamie, Lim, Malcolm, Ashwood, Lauren, Kondrashova, Olga, Lai, Andrew, Guanzon, Dominic, Scholz-Romero, Katherin, Salomon, Carlos, Martin, Andrew and Obermair, Andreas (2026). PREDICTING RESPONSE OF EARLY-STAGE ENDOMETRIOID ADENOCARCINOMA TO LEVONORGESTREL INTRAUTERINE DEVICE: DEVELOPMENT AND EVALUATION OF A PROGNOSTIC RISK MODEL FROM THE FEMME PHASE II RANDOMIZED TRIAL. International Journal of Gynecological Cancer, 36 (10) 105407, 105407. doi: 10.1016/j.ijgc.2026.105407 |
|
2026 Journal Article Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 TrialCilento, Michael A., Lin, Hui-Ming, Yeung, Nicole, Kim, Rachel M. N., Portman, Neil, Stockler, Martin R., Martin, Andrew J., Subhash, Vinod, Yip, Sonia, Butler, Lisa M., Marschner, Ian C., Meikle, Peter J., Azad, Arun A., Davis, Ian D., Horvath, Lisa G. and Sweeney, Christopher J. (2026). Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial. Prostate pros.70245. doi: 10.1002/pros.70245 |
|
2026 Journal Article Efficacy of a needle-free blood collection device (PIVO Pro) for avoiding contaminated blood culture sets in Australian emergency departments: protocol for an adaptive group sequential randomised controlled trialLovegrove, Josephine, Valks, Andrea, Ball, Daner, Harris, Patrick N A, Martin, Andrew, Langan, Gaurav, Havers, Sally, Vico Da Silva, Jonathan Javier, Keijzers, Gerben, Read, Barbara, Chan, Jason, Furlong, Karen, Schults, Jessica and Rickard, Claire (2026). Efficacy of a needle-free blood collection device (PIVO Pro) for avoiding contaminated blood culture sets in Australian emergency departments: protocol for an adaptive group sequential randomised controlled trial. BMJ Open, 16 (9) e125374, e125374. doi: 10.1136/bmjopen-2026-125374 |
|
2026 Journal Article When hierarchical composite end points do not behave as expectedWard, Eloise, Pascoe, Elaine M., Collins, Michael G., Chadban, Steven J. and Martin, Andrew J. (2026). When hierarchical composite end points do not behave as expected. Journal of the American Society of Nephrology, 37 (8), 1802-1805. doi: 10.1681/asn.0000001161 |
|
2026 Journal Article Implementation science in hybrid randomized controlled trials: a state-of-the-art systematic reviewLiu, Mark G., Comber, Elouise, Martin, Andrew, Roberts, Natasha, Trott, Mike, Costa, Nathalia, Foster, Nadine E. and Hickman, Ingrid J. (2026). Implementation science in hybrid randomized controlled trials: a state-of-the-art systematic review. JBI Evidence Implementation, 24 (3), 634-651. doi: 10.1097/xeb.0000000000000568 |
|
2026 Journal Article Pembrolizumab and denosumab in clear-cell renal-cell carcinomaHarris, Carole A., Zebic, Danka S., Morris, Michelle F., Ferguson, Tom, Goh, Jeffrey C., Martin, Andrew J., Underhill, Craig, Pook, David W., Krieger, Laurence, Kichenadasse, Ganessan, Joshi, Abhishek J., Subramaniam, Shalini, Zhang, Alison, Joshua, Anthony M., Toner, Guy C., Vasey, Paul A., Prithviraj, Prashanth, Stockler, Martin R., Davis, Ian D. and Gedye, Craig (2026). Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 24 (5) 102585, 102585-5. doi: 10.1016/j.clgc.2026.102585 |
|
2026 Journal Article Oncologist and general practitioner perspectives of telehealth-delivered colorectal cancer survivorship careLisy, Karolina, Tieu, Matthew, Laing, Erin, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, Lourenco, Richard De Abreu and Jefford, Michael (2026). Oncologist and general practitioner perspectives of telehealth-delivered colorectal cancer survivorship care. Psycho-Oncology, 35 (5) e70491. doi: 10.1002/pon.70491 |
|
2026 Journal Article Gut microbiota translocation and dissemination in health: can it be beneficial and purposeful?Udayan, Sreeram, Martin, Andrew L. and Newberry, Rodney D. (2026). Gut microbiota translocation and dissemination in health: can it be beneficial and purposeful?. Gut Microbes, 18 (1) 2662740, 1-21. doi: 10.1080/19490976.2026.2662740 |
|
2026 Journal Article Beyond bloodstream infection: the potential for hierarchical composite endpoints in vascular access researchMellander, Carl, Martin, Andrew J., Langan, Gaurav, Seifert, Stefanie, Hammarskjöld, Fredrik, Taxbro, Knut and Rickard, Claire M. (2026). Beyond bloodstream infection: the potential for hierarchical composite endpoints in vascular access research. Clinical Infectious Diseases ciag276. doi: 10.1093/cid/ciag276 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7, 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article 177 Lu-PSMA-617 SPECT/CT for early prediction of overall survival in participants with metastatic castration-resistant prostate cancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672, e252672. doi: 10.1148/radiol.252672 |
|
2026 Journal Article Radiographic progression without prostate-specific antigen progression in metastatic hormone-sensitive prostate cancer: a retrospective analysis of the ENZAMET trial (ANZUP 1304)Inderjeeth, Andrisha-Jade, Martin, Andrew J., Zielinski, Robert R., Begbie, Stephen, Cheung, Leanna, Chowdhury, Simon, Frydenberg, Mark, Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin, McCaffrey, John, McDermott, Raymond S., McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, Martin N., Sandhu, Shahneen, Tan, Alvin, Tan, Thean H., Thomson, Alastair H., Vera-Badillo, Francisco, Williams, Scott G., Thomas, Hayley, Yip, Sonia, Zhang, Alison Y., Chi, Kim N. ... Davis, Ian D. (2026). Radiographic progression without prostate-specific antigen progression in metastatic hormone-sensitive prostate cancer: a retrospective analysis of the ENZAMET trial (ANZUP 1304). European urology oncology, 9 (2), 396-403. doi: 10.1016/j.euo.2026.01.008 |
|
2026 Conference Publication How is implementation science used in hybrid effectiveness-implementation randomised controlled trials? A state-of-the-art review of early adoptersHickman, Ingrid, Liu, Mark, Comber, Elouise, Costa, Nathalia, Trott, Mike, Roberts, Natasha, Martin, Andrew and Foster, Nadine (2026). How is implementation science used in hybrid effectiveness-implementation randomised controlled trials? A state-of-the-art review of early adopters. 2025 European Implementation Event, Newcastle upon Tyne, United Kingdom, 4 - 6 June 2025. London, United Kingdom: BioMed Central. |
|
2026 Conference Publication BCG plus mitomycin (BCG plus MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, Non-Muscle-Invasive Bladder Cancer (NMIBC): Effects on urinary symptoms and other aspects of Health-Related Quality of Life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)Hayne, D., Zhang, A. Y., Thomas, H., Krieger, L., Ischia, J., Anderson, P., Srivastav, R., Green, W., Grummet, J., Bastick, P., Beardsley, E., Blatt, A., Patel, M., Mitterdorfer, A., Roberts, M., Sengupta, S., Winter, M., Cheung, L., Hawks, C., Martin, A., Mccombie, S. P., Redfern, A. D., Davis, I. and Stockler, M. R. (2026). BCG plus mitomycin (BCG plus MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, Non-Muscle-Invasive Bladder Cancer (NMIBC): Effects on urinary symptoms and other aspects of Health-Related Quality of Life (HRQL) in a randomised trial (BCGMM, ANZUP 1301). EAU26 - 41st Annual EAU Congress, London, United Kingdom, 13 - 16 March 2026. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/S0302-2838(26)00151-X |
|
2026 Journal Article Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerMunzur, Aslı D., Herberts, Cameron, Kwan, Edmond M., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Zhang, Alison Y., Williams, Scott G., Bernales, Cecily Q., Donnellan, Gráinne, Koudjanian, Melissa, Parekh, Karan, Bacon, Jack V. W., Karsan, Aly, Azad, Arun A., Davis, Ian D., Hofman, Michael S. and Wyatt, Alexander W. (2026). Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clinical Cancer Research, 32 (13). doi: 10.1158/1078-0432.ccr-25-4001 |
|
2026 Journal Article Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerSoon, Yu Yang, Marschner, Ian C., Schou, I. Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2026). Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU International, 137 (1) bju.70065, 173-180. doi: 10.1111/bju.70065 |
